000141330 001__ 141330
000141330 005__ 20240229105124.0
000141330 0247_ $$2doi$$a10.1373/clinchem.2017.281543
000141330 0247_ $$2pmid$$apmid:29483107
000141330 0247_ $$2ISSN$$a0009-9147
000141330 0247_ $$2ISSN$$a1530-8561
000141330 0247_ $$2altmetric$$aaltmetric:67519497
000141330 037__ $$aDKFZ-2018-01849
000141330 041__ $$aeng
000141330 082__ $$a610
000141330 1001_ $$aHaselmann, Verena$$b0
000141330 245__ $$aLiquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.
000141330 260__ $$aWashington, DC$$bAmerican Association for Clinical Chemistry$$c2018
000141330 3367_ $$2DRIVER$$aarticle
000141330 3367_ $$2DataCite$$aOutput Types/Journal article
000141330 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1677752269_19619
000141330 3367_ $$2BibTeX$$aARTICLE
000141330 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141330 3367_ $$00$$2EndNote$$aJournal Article
000141330 500__ $$a317
000141330 520__ $$aThe current standard for determining eligibility of patients with metastatic melanoma for BRAF-targeted therapy is tissue-based testing of BRAF mutations. As patients are rarely rebiopsied, detection in blood might be advantageous by enabling a comprehensive assessment of tumor mutational status in real time and thereby representing a noninvasive biomarker for monitoring BRAF therapy.In all, 634 stage I to IV melanoma patients were enrolled at 2 centers, and 1406 plasma samples were prospectively collected. Patients were assigned to 3 separate study cohorts: study 1 for assessment of circulating tumor DNA (ctDNA) as part of companion diagnostics, study 2 for assessment of ctDNA for patients with low tumor burden and for follow-up, and study 3 for monitoring of resistance to BRAF inhibitor (BRAFi) or mitogen-activated protein kinase inhibitor therapy.Overall, a high degree of concordance between plasma and tissue testing results was observed at 90.9% (study 1) and 90.1% (study 2), respectively. Interestingly, discrepant results were in some cases associated with nonresponse to BRAFi (n = 3) or a secondary BRAF-mutant malignancy (n = 5). Importantly, ctDNA results correlated with the clinical course of disease in 95.7% and with response to treatment. Significantly, the detection of BRAF mutant ctDNA preceded relapse assessed by Response Evaluation Criteria in Solid Tumors, and was more specific than serum S100 and lactate dehydrogenase.Blood-based testing compares favorably with standard-of-care tissue-based BRAF mutation testing. Importantly, blood-based BRAF testing correlates with the clinical course, even for early-stage patients, and may be used to predict response to treatment, recurrence, and resistance before radioimaging under BRAFi therapy, thereby enabling considerable improvements in patient treatment.
000141330 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000141330 588__ $$aDataset connected to CrossRef, PubMed,
000141330 7001_ $$0P:(DE-He78)d239d6a28875058b40c13266babadb58$$aGebhardt, Christoffer$$b1$$eFirst author
000141330 7001_ $$aBrechtel, Ingrid$$b2
000141330 7001_ $$aDuda, Angelika$$b3
000141330 7001_ $$aCzerwinski, Claudia$$b4
000141330 7001_ $$0P:(DE-HGF)0$$aSucker, Antje$$b5
000141330 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b6
000141330 7001_ $$0P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aUtikal, Jochen$$b7
000141330 7001_ $$0P:(DE-HGF)0$$aSchadendorf, Dirk$$b8
000141330 7001_ $$aNeumaier, Michael$$b9
000141330 773__ $$0PERI:(DE-600)1468161-4$$a10.1373/clinchem.2017.281543$$gVol. 64, no. 5, p. 830 - 842$$n5$$p830 - 842$$tClinical chemistry$$v64$$x1530-8561$$y2018
000141330 909CO $$ooai:inrepo02.dkfz.de:141330$$pVDB
000141330 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141330 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141330 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141330 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CHEM : 2017
000141330 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141330 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141330 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141330 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141330 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000141330 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141330 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCLIN CHEM : 2017
000141330 9141_ $$y2018
000141330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d239d6a28875058b40c13266babadb58$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000141330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000141330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000141330 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000141330 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000141330 9201_ $$0I:(DE-He78)G300-20160331$$kG300$$lKKE Dermatoonkologie$$x0
000141330 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000141330 9201_ $$0I:(DE-He78)L401-20160331$$kL401$$lDKTK Essen$$x2
000141330 980__ $$ajournal
000141330 980__ $$aVDB
000141330 980__ $$aI:(DE-He78)G300-20160331
000141330 980__ $$aI:(DE-He78)C060-20160331
000141330 980__ $$aI:(DE-He78)L401-20160331
000141330 980__ $$aUNRESTRICTED